IDENTIFICATION OF CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX AND T-CELL RECEPTOR-BINDING SITES IN THE SUPERANTIGEN TOXIC SHOCK SYNDROME TOXIN-1

被引:46
作者
HURLEY, JM
SHIMONKEVITZ, R
HANAGAN, A
ENNEY, K
BOEN, E
MALMSTROM, S
KOTZIN, BL
MATSUMURA, M
机构
[1] SUPRAGEN INC, LAKEWOOD, CO 80214 USA
[2] NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80206 USA
[3] NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DENVER, CO 80206 USA
[4] UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO 80262 USA
[5] UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA
关键词
D O I
10.1084/jem.181.6.2229
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Superantigens, in association with class II major histocompatibility complex (MHC) molecules, activate T cells bearing particular beta chain variable domains of the T cell receptor (TCR). Unlike conventional peptide antigens, superantigens bind as intact proteins to TCR and MHC molecules outside their peptide binding sites. To characterize these interactions at the molecular level, random point mutations were generated in the gene encoding toxic shock syndrome toxin 1, a bacterial superantigen associated with toxic shock syndrome. Functionally impaired mutants were identified based on their lack of murine and human T cell stimulatory activities, and experiments analyzing binding to human histocompatibility leukocyte antigen-DR molecules differentiated residues involved in MHC from TCR binding. The results showed that the great majority of mutations are clustered in two distinct regions of the toxic shock syndrome toxin 1 molecule. The class II MHC binding site is located in the hydrophobic region bf the NH2-terminal domain, and the TCR binding site is primarily in the major central groove of the COOH-terminal domain. These studies provide insight into the interactions necessary for superantigen-mediated disease in humans.
引用
收藏
页码:2229 / 2235
页数:7
相关论文
共 32 条
[1]   CHARACTERIZATION OF T-CELL REPERTOIRE CHANGES IN ACUTE KAWASAKI-DISEASE [J].
ABE, J ;
KOTZIN, BL ;
MEISSNER, C ;
MELISH, ME ;
TAKAHASHI, M ;
FULTON, D ;
ROMAGNE, F ;
MALISSEN, B ;
LEUNG, DYM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (03) :791-796
[2]   STRUCTURAL BASIS OF SUPERANTIGEN ACTION INFERRED FROM CRYSTAL-STRUCTURE OF TOXIC-SHOCK SYNDROME TOXIN-1 [J].
ACHARYA, KR ;
PASSALACQUA, EF ;
JONES, EY ;
HARLOS, K ;
STUART, DI ;
BREHM, RD ;
TRANTER, HS .
NATURE, 1994, 367 (6458) :94-97
[3]  
AIYAR A, 1993, BIOTECHNIQUES, V14, P366
[4]   MUTANTS OF STAPHYLOCOCCAL TOXIC SHOCK SYNDROME TOXIN-1 - MITOGENICITY AND RECOGNITION BY A NEUTRALIZING MONOCLONAL-ANTIBODY [J].
BLANCO, L ;
CHOI, EM ;
CONNOLLY, K ;
THOMPSON, MR ;
BONVENTRE, PF .
INFECTION AND IMMUNITY, 1990, 58 (09) :3020-3028
[5]  
BLOMSTERHAUTAMAA DA, 1986, J BIOL CHEM, V261, P5783
[6]   TOXICITY OF RECOMBINANT TOXIC SHOCK SYNDROME TOXIN-1 AND MUTANT TOXINS PRODUCED BY STAPHYLOCOCCUS-AUREUS IN A RABBIT INFECTION MODEL OF TOXIC SHOCK SYNDROME [J].
BONVENTRE, PF ;
HEEG, H ;
CULLEN, C ;
LIAN, CJ .
INFECTION AND IMMUNITY, 1993, 61 (03) :793-799
[7]   SELECTIVE EXPANSION OF T-CELLS EXPRESSING V-BETA-2 IN TOXIC SHOCK SYNDROME [J].
CHOI, YW ;
LAFFERTY, JA ;
CLEMENTS, JR ;
TODD, JK ;
GELFAND, EW ;
KAPPLER, J ;
MARRACK, P ;
KOTZIN, BL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (03) :981-984
[8]   INTERACTION OF STAPHYLOCOCCUS-AUREUS TOXIN SUPERANTIGENS WITH HUMAN T-CELLS [J].
CHOI, YW ;
KOTZIN, B ;
HERRON, L ;
CALLAHAN, J ;
MARRACK, P ;
KAPPLER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8941-8945
[9]   BIMODAL DISTRIBUTION OF V-BETA-2(+)CD4(+) T-CELLS IN HUMAN PERIPHERAL-BLOOD [J].
CLARKE, GR ;
REYBURN, H ;
LANCASTER, FC ;
BOYLSTON, AW .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (04) :837-842
[10]   EVIDENCE FOR SUPERANTIGEN INVOLVEMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS ETIOLOGY [J].
CONRAD, B ;
WEIDMANN, E ;
TRUCCO, G ;
RUDERT, WA ;
BEHBOO, R ;
RICORDI, C ;
RODRIQUEZRILO, H ;
FINEGOLD, D ;
TRUCCO, M .
NATURE, 1994, 371 (6495) :351-355